

B G Feagan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5704806/b-g-feagan-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

381
papers

45,554
citations

90
h-index

211
g-index

446
ext. papers

53,711
ext. citations

9.2
avg, IF

7.02
L-index

#	Paper	IF	Citations
381	P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn's disease in healthy first-degree relatives. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i596-i597	1.5	
380	OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i025-i026	1.5	2
379	OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. <i>Journal of Crohn's and Colitis</i> , 2022 , 16, i012-i018	1.5	4
378	Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.. <i>Gastroenterology</i> , 2022 ,	13.3	12
377	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 β stabiliser, for treatment of ulcerative colitis.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 401	6.1	0
376	Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. <i>Gastroenterology and Hepatology</i> , 2022 , 18, 14-27	0.7	
375	Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. <i>Lancet, The</i> , 2022 , 399, 2015-2030	40	8
374	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. <i>Lancet, The</i> , 2022 , 399, 2031-2046	40	5
373	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 873-886	6.1	6
372	Review of the Landmark VARSITY Trial. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 330-332	0.7	
371	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	5
370	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2021 , 19, 608	2.5	
369	Clinical, endoscopic and safety placebo rates in induction and maintenance trials of Crohn's disease: Meta-analysis of Randomised controlled trials. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	1
368	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2021 ,	0.7	1
367	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	6
366	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 ,	18.8	7
365	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1442-1453	6.1	1

364	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2031-2045.e11 ²⁰	6.9	17
363	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 994-1007	4.5	17
362	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2021 , 1	4	0
361	International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. <i>Gut</i> , 2021 ,	19.2	4
360	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. <i>Journal of Crohn's and Colitis</i> , 2021 ,	1.5	4
359	Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
358	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , 2021 , 160, 2291-2302	13.3	10
357	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2372-2384	4.0	36
356	Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 639-646	4.5	1
355	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 784-793	6.1	3
354	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. <i>Journal of Crohn's and Colitis</i> , 2021 , 15, 1120-1129	1.5	16
353	Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1513-1524	4.5	1
352	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Drugs</i> , 2021 , 81, 333-347.1	2.1	4
351	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	1
350	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	16
349	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2021 ,	11.5	4
348	Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. <i>Scientific Reports</i> , 2021 , 11, 18243	4.9	2
347	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021 , 385, 1280-1291	59.2	35

346	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021 , 161, 778-784	13.3	
345	Development of Anti-fibrotic Therapy in Stricturing Crohn's Disease: Lessons from Randomized Trials in Other Fibrotic Diseases. <i>Physiological Reviews</i> , 2021 ,	47.9	2
344	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 957-958	6.1	
343	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 1108-1117	6.1	2
342	Systematic review: medical therapy for fibrostenosing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1233-1246	6.1	11
341	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2020 , 5, CD012877	5.2	1
340	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020 , 159, 1262-1275.e7	13.3	33
339	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020 , 115, 885-894	0.7	6
338	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 819-828	18.8	42
337	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2952-2961.e8	6.9	21
336	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020 , 158, 2123-2138.e8	13.3	75
335	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2500-2509.e1	6.9	8
334	OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, S024-S025	1.5	6
333	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 304-313	4.5	6
332	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1574-1582	6.1	4
331	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	3
330	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 515-523	4.5	4
329	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1121-1132.e2	6.9	8

328	Global burden of inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 2-3	18.8	53
327	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. <i>American Journal of Gastroenterology</i> , 2020 , 115, 738-745	0.7	32
326	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 424-431.e7	6.9	9
325	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 435-445	6.1	11
324	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 553-564	6.1	13
323	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <i>Current Treatment Options in Gastroenterology</i> , 2020 , 18, 15	2.5	0
322	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <i>Gastroenterology</i> , 2020 , 159, 2013-2018.e7	13.3	3
321	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	8
320	P185 A comparison of early response parameters to inform a treat-to-target approach in ulcerative colitis. <i>Journal of Crohns and Colitis</i> , 2020 , 14, S231-S231	1.5	
319	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , 2020 , 18, 442-461	2.5	1
318	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1008-1016	6.1	7
317	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020 , 8, CD000543	5.2	9
316	Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. <i>BioDrugs</i> , 2020 , 34, 713-721	7.9	18
315	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020 , 8, CD000544	5.2	11
314	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1353-1365	6.1	34
313	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , 2020 , 37, 4491-4518	4.1	12
312	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2020 , 14, 23-32	1.5	75
311	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2139-2141.e2	6.9	6

310	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020 , 158, 537-549.e10	13.3	57
309	Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. <i>Gastroenterology</i> , 2020 , 158, 137-150.e1	13.3	26
308	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 1760-1768.e1	6.9	7
307	Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 843-851	4.5	7
306	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1047-1066	6.1	10
305	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1086-1093	6.1	13
304	Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019 , 157, 1019-1031.e7	13.3	26
303	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019 , 157, 1007-1018.e7	13.3	82
302	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019 , 157, 1233-1244.e5	13.3	28
301	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 5-23	6.1	43
300	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 1201-1216	1.5	9
299	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1401-1409	6.1	10
298	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1188-1194	6.1	14
297	Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. <i>Drug Safety</i> , 2019 , 42, 617-632	5.1	11
296	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 473-479	2.4	98
295	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. <i>Gut</i> , 2019 , 68, 1115-1126	19.2	80
294	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2019 , 38-39, 101604	2.5	16
293	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2019 , 38-39, 101602	2.5	11

292	The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC) 2019 , 25-42		
291	P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn's disease in the STEPSTONE trial. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, S450-S450	15.5	5
290	Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 472-478	4.5	
289	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , 2019 , 68, 1162-1168	19.2	27
288	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 130-138.e7	6.9	44
287	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019 , 79, 1321-1335	12.1	30
286	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2019 ,	13.3	17
285	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 1100-1111	6.1	11
284	The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review. <i>Saudi Journal of Gastroenterology</i> , 2019 , 25, 152-158	3	1
283	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019 , 114, 733-745	0.7	22
282	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. <i>Journal of Crohn's and Colitis</i> , 2019 , 13, 50-57	1.5	39
281	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 364-374	6.1	1
280	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 31-40	6.1	48
279	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1637-1640	6.9	0
278	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 63-70	18.8	11
277	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 621-626	1.5	47
276	Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 825-833	4	42
275	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 940-950	6.1	30

274	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1879-1892	6.9	70
273	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018 , 16, 129-146	2.5	44
272	Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. <i>Applied Health Economics and Health Policy</i> , 2018 , 16, 279-288	3.4	4
271	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 154, 1660-1671	13.3	108
270	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 440-449	4.5	25
269	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 408-418	1.5	66
268	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 883-895	1.5	10
267	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1578-1596	6.1	19
266	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1407-1419.e22	6.9	29
265	OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn's disease (CD). <i>Journal of Crohn's and Colitis</i> , 2018 , 12, S016-S017	1.5	10
264	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018 , 67, 244-254	19.2	73
263	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , 2018 , 67, 61-69	19.2	22
262	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 167-177	1.5	31
261	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 637-647.e13	6.9	27
260	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2018 , 154, 61-64.e6	13.3	46
259	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 105-119	1.5	55
258	882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study. <i>Gastroenterology</i> , 2018 , 154, S-1360-S-1361	13.3	18
257	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 649-660	5.9	13

256	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 671-680	18.8	94
255	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 687-695.e10	13.3	60
254	Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1678-1688	0.7	34
253	Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2519-2528	4	8
252	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 2555-2563	4	6
251	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1714-1729.e3	6.9	18
250	An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 347-357	6.1	75
249	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <i>Journal of Crohns and Colitis</i> , 2018 , 12, 1158-1169	1.5	70
248	Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2018 , 14, 244-246	0.7	2
247	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1197-1205	0.7	31
246	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018 , 155, 1045-1058	13.3	85
245	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 2155-2164	4.5	2
244	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 65-77	6.1	80
243	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 114-126	6.1	7
242	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018 , 88, 360-369.e2	5.2	15
241	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. <i>Journal of Immunological Methods</i> , 2018 , 459, 50-54	2.5	2
240	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. <i>Gut</i> , 2017 , 66, 588-596	19.2	82
239	Development and validation of a histological index for UC. <i>Gut</i> , 2017 , 66, 50-58	19.2	151

238	Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1584-1592	0.7	26
237	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017 , 66, 839-851	19.2	478
236	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017 , 66, 1049-1059	19.2	203
235	The safety of vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 501-507	4.1	26
234	Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. <i>Drugs</i> , 2017 , 77, 363-377	12.1	25
233	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1058-1072	6.1	35
232	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1021-1042	6.1	26
231	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2017 , 389, 1699-1709	40	271
230	Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest. <i>Gastroenterology</i> , 2017 , 152, S1308-S1309	13.3	70
229	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017 , 376, 1723-1736	59.2	771
228	Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn's Disease: A Gemini 2 Post hoc Analysis. <i>Gastroenterology</i> , 2017 , 152, S597	13.3	4
227	Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 793-801	5.5	4
226	Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1047-1056	4.5	11
225	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , 2017 , 5, CD011256	5.2	18
224	Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 292-302	6.1	20
223	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017 , 7, e016146	3	26
222	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 921-929	1.5	99
221	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , 2017 , 153, 77-86.e6	13.3	162

220	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017 ,	5.2	78
219	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1658-1669	0.7	23
218	The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. <i>Gastroenterology Clinics of North America</i> , 2017 , 46, 661-677	4.4	7
217	Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn's Disease. <i>Gastroenterology</i> , 2017 , 152, S1310	13.3	4
216	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017 , 152, S602	13.3	7
215	Alicaforsen for the treatment of inflammatory bowel disease. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 991-997	5.9	19
214	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 516-528	6.1	28
213	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 264-275	6.1	27
212	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 246-255	1.5	13
211	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 229-239.e5	6.9	112
210	Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 35-46	1.5	76
209	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , 2017 , 9, CD011572	5.2	12
208	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017 ,	5.2	1
207	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, S371	0.7	4
206	Benefits, Concerns, and Future Directions of Biosimilars in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 745-747	0.7	
205	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 412-424	1.5	112
204	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 400-411	1.5	109
203	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 348-354.e17	6.9	217

202	Ozanimod Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016 , 375, e17	59.2	9
201	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 157-69	6.1	37
200	Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1006-14	1.5	20
199	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 1946-1960	59.2	896
198	The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1737-43	4.5	4
197	Sa1937 Exposure-Response Relationship for Certolizumab Pegol During the Induction Phase in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2016 , 150, S409	13.3	2
196	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016 , 4, CD000543	5.2	51
195	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , 2016 , 65, 1119-25	19.2	49
194	Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee. <i>BMJ Open</i> , 2016 , 6, e009949	3	38
193	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016 , 150, 1568-1578	13.3	171
192	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 607-18	1.5	23
191	Association Between Response to Etrolizumab and Expression of Integrin β and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016 , 150, 477-87.e9	13.3	101
190	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016 , 65, 1447-55	19.2	102
189	Update on Tofacitinib for Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 572-574		2
188	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016 , CD000544	5.2	60
187	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016 , 374, 1754-62	59.2	276
186	Emerging Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2016 , 34 Suppl 1, 67-73	3.2	3
185	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1599-1607	0.7	214

184	SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2015 , 81, 489-501.e26	5.2	231
183	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <i>Gastroenterology</i> , 2015 , 148, 1035-1058.e3	13.3	251
182	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohns and Colitis</i> , 2015 , 9, 607-16	1.5	40
181	Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1151-9	4.5	50
180	Vedolizumab for the treatment of inflammatory bowel diseases. <i>Clinical Investigation</i> , 2015 , 5, 247-255		3
179	The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. <i>Gut</i> , 2015 , 64, 1539-45	19.2	192
178	Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 987-97	4.1	17
177	Vedolizumab for the treatment of moderately to severely active ulcerative colitis. <i>Pharmacotherapy</i> , 2015 , 35, 412-23	5.8	12
176	C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2015 , 110, 802-19; quiz 820	0.7	319
175	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015 , 64, 1765-73	19.2	49
174	Combination therapy for the treatment of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 1429-42	5.4	1
173	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1324-38	0.7	1024
172	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet, The</i> , 2015 , 386, 1825-34	40	279
171	A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 77-86	6.1	93
170	Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. <i>Gut</i> , 2015 , 64, 77-83	19.2	113
169	Treat to target: a proposed new paradigm for the management of Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1042-50.e2	6.9	190
168	A phase II study of laquinimod in Crohn's disease. <i>Gut</i> , 2015 , 64, 1227-35	19.2	55
167	Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. <i>Gastroenterology</i> , 2015 , 148, 37-51.e1	13.3	162

166	Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 504-14	6.1	51
165	Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 188-202	6.1	158
164	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1170-81	6.1	59
163	New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2948-57	4.5	1
162	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1200-10	6.1	71
161	Briakinumab for treatment of Crohn's disease: results of a randomized trial. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1329-40	4.5	58
160	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2475-82	4.5	23
159	Assessment of mucosal healing in inflammatory bowel disease: review. <i>Gastrointestinal Endoscopy</i> , 2015 , 82, 246-55	5.2	55
158	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 1158-69	6.1	36
157	A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. <i>Saudi Journal of Gastroenterology</i> , 2015 , 21, 185-97	3	4
156	T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. <i>Drugs</i> , 2014 , 74, 297-311	12.1	33
155	Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , 2014 , 146, 96-109.e1	13.3	482
154	Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 121-2	6.1	
153	Drug therapies and the risk of malignancy in Crohn's disease: results from the TREATRegistry. <i>American Journal of Gastroenterology</i> , 2014 , 109, 212-23	0.7	130
152	The challenge of indication extrapolation for infliximab biosimilars. <i>Biologics</i> , 2014 , 42, 177-83	1.8	120
151	Toward a personalized medicine approach to the management of inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2014 , 109, 994-1004	0.7	37
150	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. <i>Current Treatment Options in Gastroenterology</i> , 2014 , 12, 76-89	2.5	3
149	Methotrexate for induction of remission in refractory Crohn's disease. <i>The Cochrane Library</i> , 2014 , CD003459	3.45	39

148	Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. <i>Current Gastroenterology Reports</i> , 2014 , 16, 378	5	76
147	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2014 , 384, 309-18	40	331
146	Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. <i>Gastroenterology</i> , 2014 , 147, 618-627.e3	13.3	468
145	Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. <i>Gastroenterology</i> , 2014 , 146, 85-95; quiz e14-5	13.3	572
144	Assessment of histologic disease activity in Crohn's disease: a systematic review. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 2092-103	4.5	30
143	A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1850-61	4.5	40
142	A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1126-35	6.1	78
141	Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 564-75	4.5	78
140	Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. <i>Gastroenterology</i> , 2014 , 147, 1296-1307.e5	13.3	233
139	Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. <i>Gastroenterology</i> , 2014 , 146, 681-688.e1	13.3	237
138	1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial. <i>Gastroenterology</i> , 2014 , 146, S-187	13.3	5
137	DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, S42-S43	1.5	18
136	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 478-489	0.7	1
135	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , 2013 , 369, 711-21	59.2	1328
134	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2013 , 369, 699-710	59.2	1465
133	The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. <i>Gastroenterology</i> , 2013 , 145, 149-157.e2	13.3	157
132	Reliability and initial validation of the ulcerative colitis endoscopic index of severity. <i>Gastroenterology</i> , 2013 , 145, 987-95	13.3	254
131	P592 A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2013 , 7, S248	1.5	4

130	A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 654-66	6.9	146
129	Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 1691-9	4.5	62
128	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 447-59	6.1	84
127	Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2031-40	4.5	42
126	P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease Additional Results from GEMINI 1 and 2. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, S80	4.5	12
125	Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013 , 27, 567-71		25
124	Therapeutic drug monitoring of biologics for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 349-58	4.5	96
123	Ustekinumab induction and maintenance therapy in refractory Crohn's disease. <i>New England Journal of Medicine</i> , 2012 , 367, 1519-28	59.2	813
122	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , 2012 , 61, 1693-700	19.2	995
121	Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 635-46	6.1	349
120	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1770-6	0.7	76
119	Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologics</i> , 2012 , 40, 517-27	1.8	16
118	565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). <i>Gastroenterology</i> , 2012 , 142, S-114	13.3	25
117	566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2012 , 142, S-114	13.3	31
116	Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1079-87; quiz e85-6	6.9	167
115	Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. <i>American Journal of Gastroenterology</i> , 2012 , 107, 179-94; author reply 195	0.7	117
114	Inflammatory bowel disease: a Canadian burden of illness review. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012 , 26, 811-7		187
113	Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1470-9	4.5	168

112	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012 , 61, 535-42	19.2	328
111	Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. <i>American Journal of Gastroenterology</i> , 2012 , 107, 1409-22	0.7	513
110	P-26 Vedolizumab Induction Therapy for Patients With Crohn's Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S24-S25	4.5	3
109	P-24 The Relationship Between Plasma Concentrations of Certolizumab Pegol and Clinical Efficacy: Results From the PRECISE 2 Trial. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S23	4.5	
108	Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S40-S41	4.5	1
107	P-25 Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn's Disease Patients Treated With Certolizumab Pegol in the PRECISE 2 Trial. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, S23-S24	4.5	0
106	Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. <i>Gastroenterology</i> , 2011 , 141, 1194-201	13.3	646
105	Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 33, 541-50	6.1	37
104	Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 1415-22	4.5	395
103	Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 670-678.e3	6.9	117
102	Hepatic Encephalopathy: Treatment 2010 , 636-649		1
101	Ulcer Disease and Helicobacter pylori Infection: Etiology and Treatment 2010 , 102-138		1
100	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2010 , 138, S-167-S-168	13.3	12
99	Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 233-42	4.5	152
98	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1708-16	4.5	34
97	Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohn's Disease (CD). <i>American Journal of Gastroenterology</i> , 2010 , 105, S457-S458	0.7	8
96	Anti-adhesion strategies for inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2010 , 6, 372-4	0.7	
95	Obesity Management: Considerations for the Gastroenterologist 2010 , 415-434		

- 94 Pouchitis after Restorative Proctocolectomy **2010**, 248-256
- 93 Liver Transplantation: Prevention and Treatment of Infection **2010**, 724-739
- 92 Hepatitis B: Prognosis and Treatment **2010**, 448-464
- 91 Drug-Induced Diarrhea **2010**, 267-279
- 90 Non-Histological Assessment of Liver Fibrosis **2010**, 554-561
- 89 Metabolic Bone Disease in Gastrointestinal Disorders **2010**, 280-300
- 88 Management of HCV Infection and Liver Transplantation **2010**, 740-747
- 87 Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis **2010**, 619-635
- 86 Fulminant Hepatic Failure: Treatment **2010**, 661-684
- 85 Non-Steroidal Anti-Inflammatory Drug-Induced Gastro-Duodenal Toxicity **2010**, 139-164
- 84 Functional Dyspepsia **2010**, 190-199
- 83 Colorectal Cancer: Population Screening and Surveillance **2010**, 311-323
- 82 Ogilvie's Syndrome **2010**, 377-384
- 81 Colorectal Cancer in Ulcerative Colitis: Surveillance **2010**, 301-310
- 80 Hepatic Outflow Syndromes and Splanchnic Venous Thrombosis **2010**, 603-618
- 79 Microscopic Colitis: Collagenous and Lymphocytic Colitis **2010**, 257-266
- 78 Gallstone Disease **2010**, 385-395
- 77 Acute Non-Variceal Gastrointestinal Hemorrhage: Treatment **2010**, 165-189

76	Non-Alcoholic Fatty Liver Disease 2010 , 475-483		
75	Barrett's Esophagus 2010 , 62-77		
74	Celiac Disease: Diagnosis, Treatment and Prognosis 2010 , 200-210		1
73	Prevention and Treatment of Travelers' Diarrhea 2010 , 324-334		1
72	Clostridium Difficile Associated Disease: Diagnosis and Treatment 2010 , 335-354		3
71	Portal Hypertensive Bleeding 2010 , 562-602		6
70	Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders 2010 , 78-92		1
69	Liver Transplantation: Prevention and Treatment of Rejection 2010 , 685-723		2
68	Management of HBV Infection and Liver Transplantation 2010 , 748-761		1
67	Liver Biopsy 2010 , 762-770		0
66	Drug Induced Liver Disease: Mechanisms and Diagnosis 2010 , 771-786		0
65	Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1976-83	0.7	32
64	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Gut</i> , 2009 , 58, 1354-62	19.2	42
63	Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 1032-41	6.1	80
62	Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. <i>Gastroenterology</i> , 2009 , 137, 1250-60; quiz 1520	13.3	377
61	P-0068: Natalizumab reduces the rate of hospitalization in moderate to severe Crohn's Patients: Evidence from the Clinical Trial Program. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, S27	4.5	1
60	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 674-88	6.1	76
59	A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. <i>Gastroenterology</i> , 2008 , 135, 1130-41	13.3	614

58	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. <i>Lancet, The</i> , 2008 , 371, 660-667	4.0	957
57	Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1218-24	6.9	301
56	Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1370-7	6.9	236
55	A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2284-92	0.7	80
54	Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. <i>Gastroenterology</i> , 2007 , 132, 1672-83	13.3	505
53	A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. <i>Gastroenterology</i> , 2007 , 132, 763-86	13.3	724
52	Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2737-46	0.7	40
51	The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. <i>American Journal of Gastroenterology</i> , 2007 , 102, 794-802	0.7	139
50	Certolizumab pegol for the treatment of Crohn's disease. <i>New England Journal of Medicine</i> , 2007 , 357, 228-38	59.2	935
49	Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 621-30	6.9	724
48	Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 325-34	6.9	145
47	Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1030-8	0.7	174
46	Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. <i>Gut</i> , 2006 , 55, 1568-74	19.2	105
45	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 617-28	6.1	35
44	Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. <i>New England Journal of Medicine</i> , 2005 , 352, 2499-507	59.2	633
43	Infliximab for induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2005 , 353, 2462-76	59.2	2906
42	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 21, 373-84	6.1	31
41	Natalizumab induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , 2005 , 353, 1912-25	59.2	764

40	Infliximab maintenance therapy for fistulizing Crohn's disease. <i>New England Journal of Medicine</i> , 2004 , 350, 876-85	59.2	1727
39	CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. <i>Gut</i> , 2004 , 53, 1485-93	19.2	121
38	5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. <i>Clinical Gastroenterology and Hepatology</i> , 2004 , 2, 376-8	6.9	40
37	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. <i>Gastroenterology</i> , 2004 , 126, 402-13	13.3	810
36	The effectiveness of budesonide therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002 , 16, 1509-17	6.1	87
35	A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. <i>Gastroenterology</i> , 2002 , 122, 512-30	13.3	516
34	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. <i>Lancet, The</i> , 2002 , 359, 1541-9	40	3264
33	An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. <i>Gastroenterology</i> , 2001 , 120, 1330-8	13.3	227
32	Infliximab in the treatment of Crohn's disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000 , 14 Suppl C, 6C		4
31	A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. <i>New England Journal of Medicine</i> , 2000 , 342, 1627-32	59.2	593
30	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , 2000 , 118, A874	13.3	73
29	Annual cost of care for Crohn's disease: a payor perspective. <i>American Journal of Gastroenterology</i> , 2000 , 95, 1955-60	0.7	157
28	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. <i>Gastroenterology</i> , 2000 , 119, 1473-82	13.3	427
27	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. <i>Gastroenterology</i> , 1999 , 117, 527-35	13.3	195
26	Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. <i>Gastroenterology</i> , 1999 , 117, 49-57	13.3	287
25	Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 1997 , 11 Suppl 3, 98-107; discussion 107-8	6.1	35
24	A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. <i>American Journal of Hypertension</i> , 1997 , 10, 58-67	2.3	86
23	Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. <i>Gastroenterology</i> , 1996 , 110, 275-83	13.3	34

22	Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. <i>Gastroenterology</i> , 1996 , 110, 45-51	13.3	252
21	Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. <i>New England Journal of Medicine</i> , 1995 , 332, 292-7	59.2	782
20	Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. <i>New England Journal of Medicine</i> , 1994 , 330, 1846-51	59.2	222
19	Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. <i>New England Journal of Medicine</i> , 1994 , 331, 836-41	59.2	454
18	Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. <i>Gastroenterology</i> , 1994 , 106, 287-96	13.3	601
17	Colorectal Cancer in Ulcerative Colitis: Surveillance247-253		1
16	Clostridium Difficile Disease285-301		1
15	Ogilvie's Syndrome303-309		3
14	Non-Alcoholic Fatty Liver Disease393-403		1
13	Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis487-503		1
12	Fulminant Hepatic Failure527-543		1
11	Ulcer Disease and Helicobacter Pylori83-116		1
10	Non-Variceal Gastrointestinal Hemorrhage139-159		1
9	Metabolic Bone Disease in Gastrointestinal Disorders231-246		
8	Gallstone Disease311-320		
7	Hemochromatosis and Wilson Disease405-413		
6	Barrett's Esophagus55-68		
5	Liver Transplantation: Prevention and Treatment of Rejection545-571		

4 Liver Transplantation: Prevention and Treatment of Infection 573-586

3 Management of Hepatitis B and C After Liver Transplantation 587-601

2 Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders 69-81

1 Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal Toxicity 117-138